{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xu F"],"funding":["Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences","China-Japan Friendship Hospital","National Key Research and Development Program of China","Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS)"],"pagination":["800"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12376747"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(1)"],"pubmed_abstract":["<h4>Background</h4>Individuals aged 80 and older face a notably increased risk of venous thromboembolism (VTE) and mortality after SARS-CoV-2 infection. Clinical guidelines recommend routine pharmacological thromboprophylaxis, yet its application in oldest-old patients remains insufficiently studied.<h4>Aims</h4>To assess the efficacy and safety of low-molecular-weight heparin (LMWH) thromboprophylaxis in hospitalized COVID-19 patients aged 80 years and older.<h4>Methods</h4>We conducted a multicenter, prospective cohort study enrolling in-hospital COVID-19 patients aged ≥ 80 years from six tertiary hospitals in China between December 2022 and January 2023. The clinical outcomes were VTE, all-cause mortality and bleeding events. Patients were followed up for 3 months after discharge. Multivariate Cox regression models were used to identify risk factors and evaluate the impact of LMWH prophylaxis on clinical outcomes.<h4>Results</h4>Among 1526 patients aged ≥ 80 years, 41.6% received LMWH prophylaxis. LMWH prophylaxis significantly reduced VTE risk by 50% (HR 0.50, 95% CI 0.33-0.75) and mortality risk by 20% (HR 0.80, 95% CI 0.65-0.99), without increasing bleeding risk (HR 0.90, 95% CI 0.60-1.34). Male, history of stroke, critical illness on admission and hemoglobin < 90 g/L were identified as risk factors of bleeding. LMWH prophylaxis remained effective in preventing VTE and demonstrated favorable safety particularly in male patients and patients with hemoglobin < 90 g/L.<h4>Discussion and conclusion</h4>LMWH may be safe and effective for thromboprophylaxis in the oldest-old COVID-19 patients, even in patients with high bleeding risk. Further studies are needed to verify our findings."],"journal":["European journal of medical research"],"pubmed_title":["Impact of prophylactic anticoagulation on hospitalized COVID-19 patients aged over 80 years: a multicenter prospective cohort study."],"pmcid":["PMC12376747"],"funding_grant_id":["ZRJY2023-QM20","2021-I2M-1-049","2023YFC2507201","2021-I2M-1-001"],"pubmed_authors":["Xie W","Wang B","Wang C","Chen L","Wang D","Xu F","Zhai Z","Zhang S","Liu W","Deng C","Fan G","Zhang Z","Tao Y","Zhang Y","Yang P","Wan J","Han J","Wang Y","Wu W"],"additional_accession":[]},"is_claimable":false,"name":"Impact of prophylactic anticoagulation on hospitalized COVID-19 patients aged over 80 years: a multicenter prospective cohort study.","description":"<h4>Background</h4>Individuals aged 80 and older face a notably increased risk of venous thromboembolism (VTE) and mortality after SARS-CoV-2 infection. Clinical guidelines recommend routine pharmacological thromboprophylaxis, yet its application in oldest-old patients remains insufficiently studied.<h4>Aims</h4>To assess the efficacy and safety of low-molecular-weight heparin (LMWH) thromboprophylaxis in hospitalized COVID-19 patients aged 80 years and older.<h4>Methods</h4>We conducted a multicenter, prospective cohort study enrolling in-hospital COVID-19 patients aged ≥ 80 years from six tertiary hospitals in China between December 2022 and January 2023. The clinical outcomes were VTE, all-cause mortality and bleeding events. Patients were followed up for 3 months after discharge. Multivariate Cox regression models were used to identify risk factors and evaluate the impact of LMWH prophylaxis on clinical outcomes.<h4>Results</h4>Among 1526 patients aged ≥ 80 years, 41.6% received LMWH prophylaxis. LMWH prophylaxis significantly reduced VTE risk by 50% (HR 0.50, 95% CI 0.33-0.75) and mortality risk by 20% (HR 0.80, 95% CI 0.65-0.99), without increasing bleeding risk (HR 0.90, 95% CI 0.60-1.34). Male, history of stroke, critical illness on admission and hemoglobin < 90 g/L were identified as risk factors of bleeding. LMWH prophylaxis remained effective in preventing VTE and demonstrated favorable safety particularly in male patients and patients with hemoglobin < 90 g/L.<h4>Discussion and conclusion</h4>LMWH may be safe and effective for thromboprophylaxis in the oldest-old COVID-19 patients, even in patients with high bleeding risk. Further studies are needed to verify our findings.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-06-01T13:52:37.876Z","creation":"2026-04-08T13:06:01.582Z"},"accession":"S-EPMC12376747","cross_references":{"pubmed":["40855333"],"doi":["10.1186/s40001-025-03041-0"]}}